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our view, the effect of income does not only reflect money they lost.
CONCLUSIONS: An assumed income reduction clearly influenced utility scores,
however compensation for lost income fail to improve utility scores. Our results
suggest that income does not significantly influence utility scores and that the
impact of double counting is negligible.
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OBJECTIVES: To review published cost-utility analyses (CUA) targeted towards
populations in Asia.METHODS:We examined data from the Tufts Medical Center
Cost-Effectiveness Analysis Registry (www.cearegisty.org), which contains de-
tailed information on more than 2,900 English-language CUAs in peer-reviewed
journals. We focused on articles pertaining to Asian countries, summarized study
features for articles published from 2000-2010, and compared those with CUAs in
all other countries. RESULTS: Of 2,367 CUAs published during 2000-2010, 87 (3.7%)
pertained to Asian countries: Japan (n34), Taiwan (n18), China (n9), Thailand
(n7), Hong Kong (n5), Singapore (n5), South Korea (n5), India (n4), and
Bangladesh (n1). The CUAs contained 243 standardized incremental cost-effec-
tiveness ratios (ICERs, expressed as $US2010 per QALY) and 357 utility weights. The
most common type of intervention was pharmaceuticals (52.9%), followed by
screening (21.8%), diagnostics (11.5%), and surgery (11.5%). 79 CUAs (90.8%) men-
tioned a cost-effectiveness threshold; of these, 60 said “good value for money”
reflected a threshold below $50,000/QALY. The median reported ICER was $11,000/
QALY, vs. $21,000/QALY for non-Asian studies. 75.7% of the reported ICERs were
either dominant (less expensive and more effective) or below $50,000/QALY, com-
pared to 63.9% in non-Asian CUAs (p0.001). 13.6% of ICERs were either dominated
(more expensive and less effective) or greater than $100,000/QALY, compared to
22.4% in non-Asian CUAs (p0.001). CUAs targeted towards Asian populations gen-
erally adhered to good methodological practices, though the average quality score
wasmodestly lower than the overall mean (4.08 vs. 4.43, p0.001) and significantly
more studies did not report funding sources (40.2% vs. 22.2%, p0.001), compared
with non-Asian CUAs. CONCLUSIONS: The number of CUAs in Asia has grown
steadily with over half focused on pharmaceuticals. Compared to CUAs in all other
countries, significantly more studies in Asia suggest efficient health interventions.
These CUAs generally follow good methodological practices though reporting of
funding sources could improve.
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OBJECTIVES: Indirect cost is an important component in cost-of-illness assess-
ment. This study explored the factors involved in the variation of reported indirect
cost and investigated the feasibility of transferring indirect costs across settings.
METHODS: A systematic literature review was conducted to identify studies esti-
mating indirect costs for four selected chronic diseases, namely, asthma (AS), dia-
betes (DI), rheumatoid arthritis (RA), and schizophrenia (SC). Multiple linear regres-
sion was run to identify the factors that potentially explain the variation of
reported indirect costs. Parametric (fixed and random-effect model) and non-para-
metric (bootstrappingmethod)meta-analyses were applied to local gross domestic
product (GDP) per capita adjusted indirect costs for each disease. RESULTS: Sys-
tematic literature review identified 77 articles that reported indirect costs of AS
(18), DI (20), RA (25), and SC (14) for literature synthesis. Substantial inter- and
intra-disease variations among the indirect cost studies were observed, regarding
the geographic distribution, methodology and magnitude of cost estimation. Re-
gression analysis showed disease categories and local GDP per capita significantly
(P0.001) contributed to the variance of indirect cost. The range of intra-disease
variation in indirect cost was subsatntially reduced after adjusting by and express-
ing as of local GDP/capita. GDP adjusted indirect cost in terms of percentage of local
GDP/capita of AS was the lowest and that of SC was the highest. Bootstrapping
estimation was relatively conservative with slightly larger confidence intervals
than the parametric method with themean (95%CI) of 2.12% (1.4089, 2.9332) on AS,
10.65% (7.215, 14.7438) on DI, 21.98% (17.4360, 27.0631) on RA, and 79.19% (52.4243,
117.833) on SC. CONCLUSIONS: It would be convenient and feasible to construct a
universal reference range of indirect cost for a specific disease based on existing
data and presented as a percentage of local GDP to assist local decision making in
jurisdictions where indirect cost data are not available.
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OBJECTIVES: Singapore has a modified universal health care system in which sub-
sidy rates are pegged to household incomes and other socioeconomic attributes.
Out-of-pocket charges vary considerably for each service and level of subsidy.
Hence, costing issue needs to be carefully considered in cost utility study in the
context of Singapore, depending on the perspective from which the analyses are
performed. This research was to explore the costing consideration for different
possible scenarios through an illustrative cost utility analysis. METHODS: Using
the incremental cost and QALY gained data presented in a published cost utility
analysis of a treatment for breast cancer in the context of Singapore, hypothetical
scenarioswere assumed for different levels of subsidy (50%, 75% and 100%) covered
by the public health care provider that a patient might receive at a government
restructure hospital. Assuming the QALY gained remains the same, incremental
cost per QALY gained (ICER) was computed for each scenario from the perspective
of the public health care provider. RESULTS: For a fully subsidy scenario (100%), the
total incremental costwas S$62,770. In the case of subsidy rates at 50%and 75%, the
incremental total costs were S$31,385 and S$47,077, respectively. For the same
expected gained of 1.70 QALYs, the resulting ICERs were S$18,462, S$27,692 and
S$36,924 for scenarios of 50%, 75% and 100% subsidy rates, respectively.
CONCLUSIONS: Due to the possible different subsidy rates for most of the costing
items in a cost utility analysis, careful considerationwith explicit cost computation
from a clearly defined perspective is recommended. Aweighted total cost based on
the distribution of possible subsidy levels and relevant sensitivity analyses should
be considered in a pharmacoeconomic study from the perspective of the public
health care provider of Singapore.
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OBJECTIVES: Both Korea and Australia have stringent pharmaco-economic (PE)
guidelines outlining the data requirements for cost effectiveness analysis (CEA).
The requirements for regulatory approval in both countries are clear and mainly
rely on multinational clinical trials with the addition of relative small bridging
studies in Korea. It seems, however, to be different for reimbursement submission
where CEAs are presented.The purpose of this study is to uncover the data require-
ments for CEA from an industry perspective.METHODS: Firstly a literature search
was performed to find any relevant publications. Moreover website of decision
maker’s were searched for past reimbursement decisions. Finally a qualitative
comparison was made of the PE guidelines for Korea and Australia. RESULTS: The
literature search revealed very little published literature on CEAs as part of drug
reimbursement submissions inKorea andAustralia. Decisionmakers in both coun-
tries publish reimbursement decisions on their respective website. However the
information disclosed rarely reveals what input data was used for CEAs. The PE
guidelines for the respective countries showed remarkable similar data require-
ments. The main difference is surrounding local resource data. In Korea this usu-
ally retrieved through information gathering exercises like cost and utilisation
studies. It is quite different in Australia where most information is available either
through a government website or as IMS data. CONCLUSIONS: Both Korea and
Australia has specific requirements for CEAs however the local data needed for
each country differs significantly. Acquiring cost and utilisation data in Australia
seems straight forward in most cases, whereas the situation is different in Korea.
Not only does it have an impact on time to market for new innovative pharmaceu-
ticals but it also increases the uncertainty surrounding the result of the CEA mak-
ing it more difficult for decision makers to make a decision.
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OBJECTIVES:The PROLabels database (www.mapi-prolabels.org) is a unique online
tool collecting information on the medical and biological products for which the
Food and Drug Administration (FDA) and the European Medicines Agency (EMA)
have granted a Patient-Reported Outcome (PRO) labeling claim. The purpose of this
abstract is to present an overview of the database six years after its implementa-
tion in April 2006. METHODS: To create the database, data were retrieved on the
EMA website, from the European Public Assessment Reports for all the drugs ap-
proved through a centralized procedure since 1995. Evidence of a PRO endpointwas
pulled for each product from the Summary of Product Characteristics and, when
necessary, additional information was gathered from the scientific discussions.
From the FDAwebsite, datawere collected from the approved labels and additional
information was retrieved in the Medical Reviews. The database now contains all
drugs approved or revised by the FDA since 1995, including Biological Approvals
(BLAs). For the purpose of this review, all approvals between 1995 and 2011 were
reviewed individually for each agency. RESULTS: As of December 31, 2011, the
database contains 486 records of which 342 products were approved by the FDA
(22.6% of all FDA approvals). Therewere 144 productswith a PRO claim approved by
the EMA (24.2% of all EMA approvals). Nervous system diseases is the therapeutic
area for which the highest number of products is approved with a PRO claim
(n153), followed by the immune system diseases (n105). Signs and symptoms
are the most frequently measured PROs while health-related quality-of-life repre-
sents only 16.9% of all drugs approved with a PRO claim. CONCLUSIONS: The
PROLabels database provides easy access to information regarding PRO claims in
approved labels for both FDA and EMA in one location and information about PRO
claims trends in the USA and Europe.
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OBJECTIVES: Large, nationally-representative data sources of epidemiological and
health outcome information are scarce in Japan. The aim of this study was to
assess the evidence for validity of a national patient-reported survey of the adult
Japanese population comparedwith existing population-based studies.METHODS:
The data source for this comparison was the 2010 Japan National Health andWell-
ness Survey (NHWS) (N25,000). The NHWS is a self-reported, Internet-based sur-
vey administered to the adult population of Japan. A random stratified sampling
framework was implemented, with age and gender strata, to ensure the final
NHWS sample was identical to the demographic composition of the Japanese pop-
ulation. Sampling weights were applied to all analyses to project to the entire
country’s population. Prevalence statistics generated from NHWS were then com-
pared with existing epidemiological information obtained through literature
reviews. RESULTS: For certain conditions defined by clinical measures that pa-
tients may not be aware of (e.g. COPD), large differences in prevalence between
NHWS (COPD  1.37%) and the literature (10.9% reported airflow limitations in
Fukuchi et al., 2004) were observed. In these cases, differences generally disap-
peared when analyses focused purely on prevalence of awareness of diagnosis
(NHWS 1.37% vs. Fukuchi et al., 2004: 1.02%). Though some differences were ob-
served, most other conditions were generally similar between NHWS and the lit-
erature (e.g., atrial fibrillation: 0.73% vs. 0.56%, respectively; asthma: 2.55% vs.
3.40%, respectively). CONCLUSIONS: Although population-level data in Japan are
scarce, patient-reported data can provide useful epidemiological estimates as well
as valuable health outcome data across a variety of conditions. In many instances,
NHWS prevalence rates were comparable to other sources though, because the
NHWS is purely self-report, it provides a perspective based on awareness of diag-
nosis, whichmay not be relevant for all disease. Further comparisons between the
NHWS and other population-based studies are warranted.
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OBJECTIVES: National statistics on the epidemiology and health outcomes associ-
ated with various conditions are difficult to obtain in China. The aim of this study
was to assess the evidence for validity of a patient-reported survey compared with
existing epidemiological data on prominent chronic conditions. METHODS: The
data source for this comparison was the 2010 China National Health andWellness
Survey (NHWS) (N19,954). The NHWS is a self-reported survey administered to
the adult population of urban China using a mixed methodology (an Internet sur-
vey and computer assisted web interviews). A random stratified sampling frame-
work was implemented to ensure the final NHWS sample was identical to the
demographic composition of the urban China population. Horvitz-Thompson sam-
plingweights were applied to all analyses to project to the entire urban population.
Existing epidemiological information was obtained through literature reviews.
RESULTS: A prior systematic review of rheumatoid arthritis across China esti-
mated the pooled prevalence across 41 studies at 0.37%. The NHWS estimated the
prevalence in urban China at 2.14%. A population-based study conducted in 2001-2
using objective clinical measures (fasting blood glucose test and oral glucose tol-
erance test), estimated the prevalence of type 2 diabetes (T2D) at 6.1%, with 2.1%
having been diagnosed. The NHWS estimated the diagnosed prevalence of T2D at
2.95%. Other conditions were generally similar between NHWS and the literature.
CONCLUSIONS: These results suggest that a self-reported patient survey can pro-
vide useful information about the urban Chinese population. The reliance on self-
report underestimates conditions defined by clinical measures that the patient
may not be aware of (e.g., diabetes, COPD) and may result in measurement error
due tomedical illiteracy (rheumatoid arthritis versus osteoarthritis) but has shown
consistency with other population studies that analyzed awareness of the condi-
tion. Further comparisons between the NHWS and other population studies are
warranted.
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OBJECTIVES: Created in 2002, the Patient-Reported Outcome and Quality of Life
Instruments database (PROQOLID) provides a detailed description of 713 generic or
disease-specific assessment tools on the Internet (www.proqolid.org). The objec-
tive of this study is to identify the PRO instruments available for use in Taiwan.
METHODS: The PROQOLID database was explored using the search engine and
selecting in the field language the key words “Chinese for Taiwan.” RESULTS: For-
ty-four questionnaireswere identified representing 6.17% of the instruments avail-
able in PROQOLID. Out of these 44 questionnaires, six were generic (e.g., Duke
Health Profile, Euroqol EQ-5D, Psychosocial Impact of Assistive Device Scale, Fer-
rans and Powers Quality of Life Index, SF-12 Health Survey, and SF-36 Health Sur-
vey). Fourteen different therapeutic areas were identified (e.g., endocrine, system
diseases, neoplasms, respiratory tract diseases, nervous system diseases, or psy-
chiatric disorders), representing 33 different indications. Only two questionnaires
were available for pediatric use (i.e., the Pediatric Quality of Life Inventory Diabetes
Module and the Pediatric Quality of Life Inventory CancerModule). Asthmawas the
most frequent indication (four questionnaires available), followed by diabetesmel-
litus (three questionnaires), Benign Prostatic Hyperplasia (BPH) (two question-
naires) erectile dysfunction (two questionnaires) and Pain (two questionnaires).
Within the therapeutic area of neoplasms, four different indications were identi-
fied (breast, cervix, lung, and ovary). Only one instrument was available for use in
Parkinson’s disease (Parkinson’s Disease Questionnaire – PDQ-39), and one for use
in Alzheimer’s disease (Clinical Dementia Rating). Not a single instrument was
identified in therapeutic areas such as bacterial infections, eye diseases, virus dis-
eases (e.g., AIDS) or otorhinolaryngologic diseases (e.g., rhinitis). CONCLUSIONS:
Results of this overview show that PRO instruments available for use in Taiwan
cover awide variety of indications. Some therapeutic areas, however, are either not
very well represented (e.g., pediatrics or nervous diseases) or not at all (e.g., infec-
tious diseases).
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OBJECTIVES: According to the Principles on Drug Reimbursement Price Approval(P-
DRPA) issued by the Bureau of National Health Insurance (BNHI) Taiwan, in the
submission of new drug application to Pharmaceutical Benefit Scheme, MTC anal-
yse of several clinical trials could be used to assess comparative effectiveness of the
new drug to the currently best treatment(s), with or without the studies directly
compared the treatments. Quality of the MTC analysis should be evaluated in a
structured way in order to digest the potentially complex analysis.METHODS:We
identify the critical points that would have impact on the validity and consistency
of the MTC analysis by reviewing the published papers of methodology of indirect
comparison of clinical trials. RESULTS: The following checking points were pro-
posed: 1) Check the analysis aim and quality of systematic review, including: topic
(patient, intervention, comparator, outcome, PICO), systematic searching for com-
pleteness of all relevant studies included, and quality of included studies and
extracted data; 2) Check the analysis method and the included materials, includ-
ing: the framework of comparison; statistical method; identify in each pair of com-
parison the number of trials included; the important characteristics of each pair of
comparison; and meta-analysis result of each comparison pair including the syn-
thesized effect and heterogeneity; and 3) Check the analysis results, including:
reanalyze the data with the proposed model; check the consistency between indi-
rect evidence and direct evidence if available; check the sensitivity by constructing
the comparison framework from simple (limited comparisons) to complex (all
comparisons) or including additional study characteristics; check the results using
different statistical models and different effect measurements (such as risk ratio,
risk difference, odds ratio etc.). CONCLUSIONS:MTC is a relatively new but poten-
tially valuable method to analyze evidence for comparing effectiveness of several
interventions. Experience of using the structural checking points will be built up.
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OBJECTIVES: Post-marketing surveillance for adverse effects has become an essen-
tial element of new drug andmedical devices development in the European Union
and the USA. The objective of this study is to present an overview of the content of
a database gathering details of Post-Marketing Requirements (PMRs), i.e., studies
requested by the following regulatory agencies: EuropeanMedicines Agency (EMA,
EU), the Food andDrugAdministration (FDA, USA), and theHaute Autorité de Santé
(HAS, France). METHODS: All drug approvals published by the EMA, the FDA, and
the HAS between January 1, 2005 and December 31, 2011 were reviewed to retrieve
PMRs. The information was categorized as follows: product description (brand
name, INN, indication, etc.), application details, PMR details, and information
source. RESULTS: For the FDA, we reviewed 763 original approvals and 944 supple-
ments and included, respectively, 201 and 110 drugs approved with PMRs. For the
EMA, we reviewed 349 marketing authorizations and included 38 files with PMRs.
For theHAS, 3674 opinionswere publishedwith only 174 opinionswith PMRs.Many
HAS requests were long-term follow-up studies. About 43% of the PMRs requested
by the FDA were pediatric studies. At present, the EMA also requires pediatric
studies but under a Pediatric Investigation Plan (PIP). Since 2005, 21 PIPs have been
requested. Nomatterwhich agency is reviewed, all kinds of indications are covered
by the PMRs, e.g., treatment of sepsis, asthma, malaria, depressive disorder, etc.
CONCLUSIONS: This project will be a unique source of centralized information
about PMRs requested in Europe and in the USA. It will be useful to observe the
trends in studies requested, to anticipate the demands, and to integrate the studies
as early as possible in the product development process. The Post-Marketing Re-
quirements database will be available online in an independent website, with ac-
cess by subscription.
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